Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several core claims about BEVESPI AEROSPHERE (COPD maintenance use; LABA/LAMA combination) align with the provided label context, but multiple statements are not supported by the supplied prescribing information excerpt (e.g., active ingredient for “Bevespi,” common side effects, and the nature of warnings).
Category Scores
Accurate Statements
Bevespi Aerosphere is a COPD inhaler.
Supported indirectly by the provided label focus on maintenance treatment of COPD (Section 1 INDICATIONS AND USAGE) and the product description as a COPD maintenance inhaled aerosol (in the provided context).
Bevespi Aerosphere contains two long-acting bronchodilators, a LABA and a LAMA.
Supported by the provided active ingredients list: glycopyrrolate (LAMA) and formoterol fumarate (LABA).
Bevespi Aerosphere is used to help prevent breathing difficulty in chronic obstructive pulmonary disease (COPD).
Supported by the label indication for maintenance treatment of COPD (Section 1 INDICATIONS AND USAGE). The excerpt does not use the phrase “prevent breathing difficulty,” but this is consistent with maintenance use to manage COPD symptoms.
Unsupported Statements
Bevespi is the brand name for beclomethasone.
The provided prescribing information excerpt identifies BEVESPI AEROSPHERE as glycopyrrolate and formoterol fumarate. It does not support a relationship to beclomethasone.
Common side effects/questions for Bevespi Aerosphere include cough, throat irritation, and dry mouth.
The provided label excerpt includes only an introductory cross-reference to adverse reactions and does not list cough, throat irritation, or dry mouth.
Bevespi Aerosphere is associated with warnings that require medical attention.
The provided excerpt shows warnings/precautions exist but does not state that any specific warnings “require medical attention.” No label language supports this wording.
Contradictions
Important Omissions
Dosage and administration details (e.g., 18 mcg/9.6 mcg twice daily; do not take more than two inhalations twice daily).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The unsupported claim linking “Bevespi” to beclomethasone could lead to product misidentification. Unsupported statements about side effects and the nature of “warnings that require medical attention” could misinform patient expectations/triage, though they do not directly alter contraindicated use in the provided excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
At least one material incorrect/unsupported identity claim (“Bevespi” as beclomethasone) plus multiple unsupported safety/side-effect/warning characterizations.
Suggested Improvement
Remove or correct the beclomethasone claim; avoid listing specific side effects (cough, throat irritation, dry mouth) unless supported by the provided label text; and use label-supported wording for warnings rather than stating they “require medical attention” without explicit label support. Add label-supported dosing limits if making dosage-related claims.